# Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

> **NCT03135054** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 40 (estimated)

## Conditions studied

- AML
- FLT3-ITD Mutation

## Interventions

- **DRUG:** Quizartinib
- **DRUG:** Omacetaxine Mepesuccinate Injection

## Key facts

- **NCT ID:** NCT03135054
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03135054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03135054, "Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03135054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*